MedTrace Logo

Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients

NCT02296567 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2015-08-11

No results posted yet for this study

Summary

To demonstrate the effects of Lucentis (ranibizumab), Avastin ( bevacizumab), and Eylea ( aflibercept) on the levels of naturally occurring Vascular Endothelial Growth Factor (VEGF) in the systemic circulation of Age Related Macular Degeneration patients currently treated with these medications.

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

Ranibizumab

Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.

DRUG

Bevacizumab

Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care.

DRUG

Aflibercept

Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care.

DRUG

Ranibizumab

Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.

DRUG

Bevacizumab

Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care

DRUG

Aflibercept

Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care

DRUG

Ranibizumab

Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care

DRUG

Bevacizumab

Drug: Bevacizumab Subjects will receive intravitreal bevacizumab as part of their routine medical care

DRUG

Aflibercept

Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care

OTHER

Control Group

Control group Subjects will no previous anti-VEGF treatment

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • East Florida Eye Institute

    lead OTHER

Principal Investigators

  • Ronald E Frenkel, MD · East Florida Eye Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02296567 on ClinicalTrials.gov